0000000000326969

AUTHOR

Erik Lagolio

showing 2 related works from this author

An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy

2021

Background & aims: Hydroxychloroquine (HCQ) and chloroquine (CQ) are anti-malarial drugs frequently used in the rheumatologic field. They were recently identified as potential therapeutic options for Coronavirus Disease (COVID-19). The present study aims to map and grade the diverse health outcomes associated with HCQ/CQ using an umbrella review approach. Methods: Umbrella review of systematic reviews of observational and intervention studies. For observational studies, random-effects summary effect size, 95% confidence interval, and 95% prediction interval were estimated. We also assessed heterogeneity, evidence for small-study effect, and evidence for excess significance bias. The quality…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyhydroxychloroquine030106 microbiologyDiseaseReviewlcsh:Infectious and parasitic diseaseslaw.inventionchloroquine03 medical and health sciences0302 clinical medicinesystematic reviewRandomized controlled triallawChloroquineInternal medicineDiabetes mellitusChloroquine; COVID-19; Hydroxychloroquine; umbrella review; COVID-19; Chloroquine; Humans; Hydroxychloroquine; SARS-CoV-2medicineHumanslcsh:RC109-216030212 general & internal medicineumbrella reviewbusiness.industrySARS-CoV-2COVID-19HydroxychloroquineChloroquineGeneral Medicinemedicine.diseaseConfidence intervalCOVID-19 Drug TreatmentInfectious DiseasesSystematic reviewObservational studybusinessmedicine.drugHumanHydroxychloroquine
researchProduct

Use of corticosteroids in Coronavirus disease 2019 pneumonia: A systematic review of the literature

2020

The aim was to investigate the effectiveness of glucocorticoid therapy in patients with COVID-19. A systematic search of the literature across nine databases was conducted from inception until 15th March 2020, following the PRISMA guidelines. Patients with a validated diagnosis of COVID-19 and using corticosteroids were included, considering all health outcomes. Four studies with 542 Chinese participants were included. Two studies reported negative findings regarding the use of corticosteroids in patients with COVID-19, i.e., corticosteroids had a detrimental impact on clinical outcomes. One study reported no significant association between the use of corticosteroids and clinical outcomes. …

medicine.medical_specialtyARDSCoronavirus disease 2019 (COVID-19)SARS-Cov-2Coronavirucoronavirus030204 cardiovascular system & hematologyHealth outcomescorticosteroids03 medical and health sciences0302 clinical medicineInternal medicineMedicineCorticosteroidpneumoniaIn patient030212 general & internal medicinelcsh:R5-920business.industryCOVID-19General Medicinemedicine.diseasemethylprednisolonePneumoniaMethylprednisoloneGlucocorticoid therapyMedicineARDSRisk of deathSystematic ReviewCOVID-19 coronavirus corticosteroids methylprednisolone pneumonia ARDS SARS-Cov-2businesslcsh:Medicine (General)medicine.drug
researchProduct